U.S. equity markets are entering a pivotal window as investors digest a tech-led recovery and prepare for a wave of top-tier economic data. After a volatile start to February, major indices have stabilized, with futures remaining steady as the focus shifts to consumer health and inflation trends. The tech sector continues to serve as the market's primary engine. The Nasdaq Composite recently led gains with a 1.0% jump, recovering from earlier sessions of deep selling. Significant momentum remains centered on AI infrastructure, with Nvidia rising nearly 3.0% and Oracle surging 9.6% following increased demand for data services. Despite this, some software and electric vehicle stocks have lagged, with Tesla falling 3.0% amid broader concerns over shifting incentives and trade policy. Consumer resilience is currently at the forefront of the economic narrative. Retail sales figures for February showed a modest 0.2% increase, a critical rebound from the 1.2% decline recorded in January. While the headline number appears slim, it brings the year-over-year growth to 3.1%, suggesting that household spending remains a pillar of support for the economy. High-performing segments include online retail, which saw a 2.4% increase, and health and personal care shops, rising 1.7%. Inflation data continues to complicate the Federal Reserve’s path. Current expectations for the Consumer Price Index (CPI) sit at a 2.9% year-over-year increase, while Core CPI is projected at 3.1%. These figures remain stubbornly above the 2.0% target, keeping Treasury yields elevated. The 10-year Treasury yield is currently hovering near 4.56%, while the 2-year yield has reached 4.94%, reflecting market bets on a "higher-for-longer" interest rate environment. Key levels to watch for the S&P 500 include the 6,070 to 6,100 resistance zone. Analysts suggest that a weekly close above this range could act as a springboard for a retest of all-time highs. Conversely, support is established at the 5,925 level. On the corporate front, Super Micro Computer has recently jumped 17.6% as investors await critical business updates, while the pharmaceutical sector has faced pressure, with Incyte tumbling nearly 8.0% on a lowered sales outlook. The broader market sentiment is one of cautious optimism. While corporate earnings remain generally supportive—with over 75% of S&P 500 companies beating estimates—the upcoming release of producer price data and employment reports will be the ultimate deciders of near-term direction. Investors are closely monitoring these metrics to determine if the current rally has the fundamental backing to withstand ongoing global trade uncertainties and persistent price pressures.